The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials
British Journal of Clinical Pharmacology, 03/19/2012Fang WT et al.
Statin therapy was significantly associated with a decreased risk of incidence or recurrence of atrial fibrillation (AF). Heterogeneity was explained by differences in statin types, patient population and surgery types. Benefit of statin therapy seemed more markedly in secondary prevention than primary prevention.
Meta analysis of randomized, controlled trials with use of statins on incidence or recurrence of AF was performed.
20 studies with 23577 patients were included in the analysis.
7 studies investigated the use of statins in patients with AF, 11 studies investigated the primary prevention of statins in patients without AF, and 2 studies investigated mix population patients.
Incidence or recurrence of AF occurred in 1543 patients.
Overall, statins therapy was significantly associated with a decreased risk of AF compared with control (OR 0.49, 95% CI 0.37 to 0.65, p <0.00001).
Beneficial effect was found in atorvastatin subgroup and simvastatin subgroup, but not found in pravastatin subgroup and rosuvastatin subgroup.
Benefit of statin therapy seemed more markedly in secondary prevention (OR 0.34, 95% CI 0.18 to 0.64, p<0.0008) than primary prevention (OR 0.54, 95% CI 0.40 to 0.74, p< 0.0001).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.